Actinium Pharmaceuticals, Inc.’s Actimab-A And Alpha-Particle Immunotherapy Platform Further Validated At Society For Nuclear Medicine Annual Meeting
Published: Jun 24, 2014
NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, provided highlights from an educational session featuring Actimab-A, a radiolabeled antibody currently in a Phase I/II clinical trial, at the 2014 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in St. Louis, MO.
Help employers find you! Check out all the jobs and post your resume.